1.70Open1.70Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover0.00%IV3.08%PremiumOct 18, 2024Expiry Date1.50Intrinsic Value100Multiplier-1DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pulmonx Stock Discussion
jp Morgan buy 860k shares
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet